NASDAQ: LPCN - Lipocine Inc.

Yield per half year: -39.48%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Lipocine Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Lipocine Inc.

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis.

more details
It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2013-10-22
ISIN US53630X1046
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.lipocine.com
Цена ао 3.47
Change price per day: -2.24% (3.12)
Change price per week: -0.3268% (3.06)
Change price per month: -12.86% (3.5)
Change price per 3 month: -33.98% (4.62)
Change price per half year: -39.48% (5.04)
Change price per year: -42.67% (5.32)
Change price per 3 year: +179.82% (1.09)
Change price per 5 year: +651.05% (0.4061)
Change price per year to date: -37.37% (4.87)
All parameters

Underestimation

Title Value Grade
P/S -5.43 0
P/BV 0.7606 9
P/E 0 0
EV/EBITDA -0.5998 0
Total: 3.63

Efficiency

Title Value Grade
ROA, % -71.09 0
ROE, % -80.28 0
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.000959 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -1827.77 0
Yield Ebitda, % 24.6 4
Yield EPS, % -63.66 0
Total: 1.8
More

Institutions Volume Share, %
Vanguard Group Inc 221459 4.17
Blackrock Inc. 74846 1.41
Susquehanna International Group, LLP 56601 1.06
Geode Capital Management, LLC 48854 0.92
Two Sigma Advisers, LP 26222 0.49
Renaissance Technologies, LLC 18797 0.35
State Street Corporation 18626 0.35
Wealth Effects LLC 14639 0.28
Tower Research Capital LLC (TRC) 2238 0.04
Morgan Stanley 722 0.01



Head Job title Payment Year of birth
Dr. Mahesh V. Patel Ph.D. Co-Founder, Interim Principal Financial Officer, Director, President & CEO 762.53k 1957 (68 years)
Ms. Krista Fogarty Principal Accounting Officer & Corporate Controller 321.07k 1968 (57 years)
Dr. Nachiappan Chidambaram Ph.D. Senior Vice President of Research & Development 385.71k 1969 (56 years)
Mr. Logan Morse Vice President of Sales, Marketing & Operations 413.58k 1970 (55 years)
Dr. Anthony DelConte M. D., M.D. Chief Medical Director 1958 (67 years)

Address: United States, Salt Lake City. UT, 675 Arapeen Drive - open in Google maps, open in Yandex maps
Website: https://www.lipocine.com